Key Stats for Eli Lilly Stock
- Stock Movement (Post-Earnings): -7.8%
- Current Price: $990
- TIKR Target Price: $2,011
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
The prevailing market narrative around Eli Lilly (LLY) is a classic case of “victim of its own success.”
Wall Street is simultaneously in awe of the company’s hyper-growth in the obesity space and terrified of what happens if that single market suddenly cracks due to pricing pressure or competition.
The sell-off was driven by rising anxieties over portfolio concentration, the fear that Eli Lilly is effectively becoming a single-product company reliant entirely on the incretin (GLP-1) space.
However, at the TD Cowen 46th Annual Health Care Conference, CFO Lucas Montarce aggressively pushed back against this narrative, highlighting a massive, diversified pipeline that is about to hit the market.
Analyst Steve Scala pushed management on whether the competition’s oral pill would cannibalize Lilly’s lead.
CFO Lucas Montarce’s response revealed a massive, unpriced catalyst: The $1.5 billion “Inventory Wall.”
Unlike the supply shortages that plagued the sector in 2024, Lilly has built a massive pre-launch inventory for its daily oral pill, Orforglipron.
This ensures that the moment the FDA gives the green light, expected in early Q2, Lilly can flood the market globally, capturing the massive “needle-phobic” patient population that currently remains untapped.
See analysts’ growth forecasts and price targets for Eli Lilly stock (It’s free!) >>>
Is Eli Lilly Undervalued Today?
The market’s knee-jerk reaction completely discounts the incoming wave of pipeline catalysts that will fundamentally expand Lilly’s Total Addressable Market (TAM) far beyond its current injectable franchise.
While Zepbound and Mounjaro (tirzepatide) remain the foundation of the business, Montarce highlighted the imminent approval of Orforglipron, a daily oral pill for obesity.
A massive patient population simply refuses to take injectable medications, meaning Orforglipron is not going to cannibalize existing sales; it will exponentially expand the market.
Furthermore, Orforglipron has already secured Medicare access starting July 1st, paving the way for explosive volume growth.
But the real alpha lies outside of the obesity spotlight.
Montarce revealed that Eli Lilly is aggressively pivoting its metabolic expertise into the cardiovascular space with two massive pipeline assets, lepodisiran and muvalaplin, designed to treat underlying cardiovascular risk (Lp(a)).
Furthermore, the company is quietly building a dominant neuroscience portfolio.
Montarce stated verbatim: “We talk about Kisunla… getting into preclinical for Alzheimer could be another unlocking of a large opportunity in terms of patients that could make — many of them will not have symptoms nowaday that could more significantly reduce the cognitive decline… That could unlock a significant opportunity.”
See how LLY stock performs against its competitors (It’s free!) >>>
When you combine a dominant 70% market share in the obesity space with a rapidly expanding cardiovascular and oncology pipeline, Eli Lilly’s premium multiple compared to its peers is entirely justified.
Valuation Deep Dive
The TIKR Advanced Model identifies Eli Lilly as the premier “hyper-growth” play in large-cap pharma, fueled by the transition from specialty injectables to mass-market orals.
- TIKR Target Price: $2,011.43
- Target Return: 103.11%
The Volume-Driven Margin Lever: The mechanical path to the $2,011.43 TIKR target relies on leveraging volume to offset pricing pressure. Montarce explicitly acknowledged that price erosion (in the mid-to-high single digits) is a reality of the pharma industry. However, by launching the highly convenient Orforglipron pill globally and scaling its automated manufacturing lines (which lowers cost of goods sold), Eli Lilly will drive massive volume growth that drastically outpaces pricing headwinds. As these new automated facilities come fully online, net income margins are modeled to expand from 26% to nearly 30%, supporting a staggering 15.8% annualized return target through 2030.
Conclusion: The market’s 7.8% punishment of Eli Lilly is a massive overreaction to generalized concentration fears. By pioneering the oral obesity market with Orforglipron, securing early Medicare access, and quietly building out a blockbuster cardiovascular and Alzheimer’s pipeline, Eli Lilly is actively derisking its future. The mathematical upside to a $2,011 valuation makes this post-earnings dip a highly attractive opportunity.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Eli Lilly?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Eli Lilly, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Eli Lilly alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Eli Lilly on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
